Research programme: B7-H3 targeting natural killer cell engaging therapeutics - Innate Pharma/Sanofi

Alternative Names: B7 H3 targeting natural killer cell engaging therapeutic - Innate Pharma/Sanofi

Latest Information Update: 20 Jan 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Innate Pharma
Developer Innate Pharma; Sanofi
Class Antineoplastics; Bispecific antibodies; Immunotherapies
Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

22 Dec 2022 Innate Pharma has patent protection for multispecific NK engager proteins in Japan, Australia and USA
22 Dec 2022 Innate Pharma has patent protection for multispecific NKp46 binding proteins in the US and Japan
22 Dec 2022 Innate Pharma has patent protection for variable regions for NKp46-binding proteins in Japan, US and China

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com